Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Tobidina

Approved

STANDARD

Tobidina

Indiana Ophthalmics🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: a2476c3ffa6e2af3
Company: Indiana Ophthalmics
Type: Standard

Approval Details

Approval Id: a2476c3ffa6e2af3
Drug Approval Philippines Name: Tobidina
Product Name: Tobidina
Registration Number: DRP-13479
Brand Name: Tobidina
Generic Name: Tobramycin (as Sulfate)
Dosage Form: Ophthalmic Ointment
Dosage Strength: 3 mg/g (0.3% w/w)
Manufacturer: Indiana Ophthalmics
Importer: Aglobal Care Inc.
Distributor: Aglobal Care Inc.
Issuance Date: 27 February 2023
Expiry Date: 27 February 2028
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

a2476c3ffa6e2af3

Type

Standard

Back to Philippines FDA Approvals

Tobidina - Philippines FDA Drug Approval Details